A real world, retrospective, multicenter study evaluating efficacy, safety of iGlarLixi in patients with Type 2 Diabetes
Latest Information Update: 18 Nov 2022
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms ENSURE
- 14 Nov 2022 Results published in the Diabetes Therapy
- 08 Aug 2021 New trial record
- 29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association